TSHA 116
Alternative Names: TSHA-116Latest Information Update: 21 May 2024
At a glance
- Originator Taysha Gene Therapies
- Class Obesity therapies; RNA
- Mechanism of Action Histone-lysine N-methyltransferase inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Prader-Willi syndrome
Most Recent Events
- 31 Dec 2023 Taysha Gene Therapies has one pending patent PCT application for RNA interference (RNAi) constructs targeting EHMT2 for the treatment of Prader-Willi Syndrome in-licensed from The Board of Regents of The University of Texas System
- 02 Sep 2020 Early research in Prader-Willi syndrome in USA (Intrathecal) (Taysha Gene Therapies)